By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

Let's focus on what we can do, not what we can't!

Online Platform By Disabled People for Disabled People

  • Home
  • >
  • Latest Headlines
  • >
  • Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy … – PR Newswire (press release)

Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy … – PR Newswire (press release)

Friday, 19 February, 2016

Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy … – PR Newswire (press release)

17, 2016 /PRNewswire/ -- Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, TXA127, for the treatment of laminin-deficient congenital muscular dystrophy ...

Read More

Source:Tarix Orphan Granted Orphan Drug Status for TXA127 as Potential Treatment for Congenital Muscular Dystrophy ... - PR Newswire (press release)

Categories :
  • Latest Headlines
  • Muscular Dystrophy
  • Uncategorized
Socials :

Recent posts

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Ability Today to your inbox.

By clicking “submit,” you agree to receive emails from Ability Today and accept our web terms of use and privacy and cookie policy.

Our Awards and Partners

Copyright © 2022 All rights reserved